CARE consortium dispatches to quicken drug discovery and improvement for COVID-19 Kumar Jeetendra | August 19, 2020 Using a grant approximately $77.7 million, CARE is funded by cash donations by the European Union (EU) and money and in-kind contributions from Australian European Federation of Pharmaceutical Industries and Associations (EFPIA) businesses and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, …
Biomarkers can foresee how hereditarily identical cells act distinctively under pressure Kumar Jeetendra | January 10, 2021 A set of biomarkers not traditionally associated with cell fate can accurately forecast how genetically identical cells behave differently under pressure, according to a UT Southwestern study. The findings, published by Cell Reports as a Dec. 1 cover story, could eventually result in more predictable responses to pharmaceutical remedies. Groups of the same types of …
Sloan Kettering Institute specialists offer news answer to 100-year-old malignancy secret Kumar Jeetendra | January 23, 2021 The year 2021 marks the 100th anniversary of a basic discovery that is taught in every biochemistry textbook. In 1921, German doctor Otto Warburg observed that cancer cells harvest energy from sugar sugar in a strangely inefficient manner: instead of”burn” it using cancer cells do what yeast do — they ferment it. This oxygen-independent process …
Malmö University educator investigates new cycle to make nutritious vegan cheese Kumar Jeetendra | January 28, 2021 As many opt for a plant-based diet, vegetarian options are big business. However, some dairy products just cannot be mimicked. Now, a Malmö University professor is on course to develop a fresh nutritious vegan cheese-making procedure. The planet’s limited resources and growing population have never been more under the spotlight. This is what prompted Marité …
FDA supports new medication for therapy of adults with chronic kidney infection Kumar Jeetendra | May 1, 2021 Today, the U.S. Food and Drug Administration accepted Farxiga (dapagliflozin) oral tablets to decrease the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression. Chronic kidney disease occurs when the kidneys are damaged and can’t filter blood …
